Join us for an exclusive event as we discuss:
- How innovations in biologics and precision medicine are shaping the future of targeted, patient-centric therapies.
- Best practices for developing and manufacturing Antibody-Drug Conjugates (ADCs) with a phase-appropriate approach to clinical trials and commercialization.
- Insights into the evolving regulatory landscape and how to navigate it effectively during drug development.
- Key supply chain strategies for Advanced Drug Delivery (ADD) platforms, including how to build scalable, low-risk models for drug-device combination products.
Agenda
9-9.30AM: Arrival and Breakfast
9.30-10.15AM: Considerations for building a Low-Risk, Highly Scalable Supply Chain for Drug Device Combination Products – Paul Smallman, Senior Director, Global Technical Sales
10.15-11AM: How to effectively navigate development and manufacturing pathways for Antibody-Drug Conjugates (ADCs) – Anshul Gupte, VP, Pharmaceutical Development
11AM-1PM: Catered Networking Exchange